Insulet Stock Performance
| PODD Stock | USD 227.08 -0.02 -0.01% |
The company secures a Beta (Systematic Risk) of 0.56, which attests to generally lower market sensitivity than the broad market. With a sub-1 beta, Insulet typically participates in market rallies at a reduced pace while often limiting downside exposure. At this point, Insulet has a negative expected return of -0.38%.
Risk-Adjusted Performance
Weak
Weak | Strong |
Over the last 90 days, Insulet generated negative risk-adjusted returns and added little value for investors with long positions. Used correctly, this score supports evaluation of raw price movement versus actual return efficiency. In spite of weak performance in the last few months, the stock's fundamental indicators remain rather sound, which may send shares a bit higher in April 2026. The latest tumult may also be a sign of longer-term up-swing for the firm's shareholders. Learn More
Actual Historical Performance (%)
One Day Return -0.01 | Five Day Return -0.36 | Year To Date Return -19.74 | Ten Year Return 621.58 | All Time Return 1.3 K |
1 | A Look At Insulet Valuation After Recent Share Price Weakness | 02/09/2026 |
2 | Insulet stock rises before hours on Street-beating Q 4, 31 percent sales growth | 02/18/2026 |
3 | Acquisition by Ashley Mc Evoy of 10046 shares of Insulet subject to Rule 16 b-3 | 02/24/2026 |
4 | Handelsbanken Fonder AB Has 6.49 Million Position in Insulet Corporation PODD | 03/03/2026 |
5 | Insulet Presents Promising Study Results for Fully Closed-Loop Automated Insulin Delivery System for Adults with Type 2 Diabetes | 03/11/2026 |
6 | Insulet Initiates Voluntary Medical Device Correction for Certain Omnipod 5 Pods in the U.S. | 03/12/2026 |
7 | Market Decliners Adobe , Ulta Beauty , and Sentinel One Drop Amid Leadership Changes and Weak Forecasts | 03/13/2026 |
8 | Jain Global LLC Has 32.95 Million Stake in Insulet Corporation PODD | 03/16/2026 |
9 | Silvant Capital Management LLC Acquires 2,655 Shares of Insulet Corporation PODD | 03/18/2026 |
10 | PODD Investor Alert Insulet Corp. Potential Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Executives Allegedly Misled... | 03/19/2026 |
| Begin Period Cash Flow | 953.4 M | |
| Total Cashflows From Investing Activities | -222.7 M |
Relative Risk vs. Return Landscape
If you had invested $ 28,882 in Insulet on December 24, 2025 and sold it today you would have lost $ 6,174 from holding Insulet or given up 21.38% of portfolio value over 90 days. Insulet does not currently generate positive expected returns and carries 2.0076% risk (volatility on return distribution) over a 90-day horizon. In different words, 18% of stocks are less volatile than Insulet, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Target Price Odds to finish over Current Price
The concept of mean reversion, where Insulet Stock price gravitates toward equilibrium, is fundamental to market analysis. This pattern is a cornerstone of many forecasting models, though periods of persistent mispricing occur. Investors demand compensation for the additional risk inherent in stocks that remain mispriced longer. The concept of price convergence is essential context for any investor forecasting Insulet Stock price direction.
| Current Price | Horizon | Target Price | Odds moving above the current price in 90 days |
| 227.08 | 90 days | 227.08 | more than 93.0 |
Statistical modeling indicates that the probability of Insulet moving above the current price in 90 days from now is more than 93.0 . That leaves the short-horizon profile tilted toward better-than-current-price outcomes. (This stock distribution maps the range in which Insulet Stock has been most likely to trade over the next 90 days).
Insulet Price Density |
| Price |
Predictive Modules for Insulet
Accurately predicting the stock market is one of the most challenging tasks for investors analyzing Insulet. No single approach dominates, but the practice of forecasting remains an essential element of the investment process. Investors benefit from applying a variety of techniques rather than relying on a single model for Insulet. The practice of comparing forecasts for Insulet builds analytical resilience regardless of which model proves most accurate.Experienced investors tracking Insulet's watch for mean reversion setups where price has deviated from its long-run average. Sentiment extremes, news events, or liquidity shocks are common catalysts for these temporary dislocations in Insulet. Prices periodically overshoot their intrinsic value in both directions, creating mean reversion opportunities in Insulet. The mean reversion signal is most useful when combined with fundamental confirmation for Insulet's.
Primary Risk Indicators
Volatility has been a defining feature of the stock market in recent decades, and Insulet has reflected that pattern. Sudden corrections and sharp rallies have tested many portfolios that include Insulet. A risk management approach built around Insulet's volatility metrics can help investors manage downside exposure. Tracking Insulet's risk indicators over time reveals how the risk profile evolves across market cycles.α | Alpha over Dow Jones | -0.3164 | |
β | Beta against Dow Jones | 0.56 | |
σ | Overall volatility | 22.81 | |
Ir | Information ratio | -0.1468 |
Investor Alerts and Insights
For investors following Insulet, automated alerts provide early signals of meaningful shifts in stock dynamics. Insulet notifications highlight material changes that could affect portfolio decisions and overall risk exposure. Investors can customize Insulet alert parameters to match their risk tolerance and investment horizon. Pairing alerts with independent analysis strengthens conviction in Insulet investment decisions.| Insulet generated a negative expected return over the last 90 days | |
| Insulet is unlikely to experience financial distress in the next 2 years | |
| Over 100.0% of the company shares are owned by institutional investors | |
| Latest headline from globenewswire.com: Halper Sadeh LLC is Investigating Whether SEM, UNF, ACLX, FONR are Obtaining Fair Deals for their Shareholders |
Price Density Drivers
For Insulet, price shifts are largely a function of buyer and seller positioning dynamics and broader market conditions. Key market indicators for Insulet Stock are presented below to contextualize recent price movements. Tracking Insulet's market indicators provides context for distinguishing fundamental shifts from short-term noise. This data helps frame whether current Insulet's price movements warrant further investigation.
| Common Stock Shares Outstanding | 71.9 M | |
| Cash And Short Term Investments | 716.1 M |
Insulet Fundamentals Growth
The pricing of Insulet Stock is heavily influenced by Insulet's fundamental performance over time. Investors monitor revenue growth, profit margins, cash flow generation, and debt management as key indicators. The performance of Insulet Stock is closely linked to Insulet's underlying financial metrics and growth rates. Profitability trends, cash flow generation, and capital structure remain the key fundamentals for Insulet Stock.
| Return On Equity | 0.18 | |||
| Return On Asset | 0.0943 | |||
| Profit Margin | 0.09 % | |||
| Operating Margin | 0.19 % | |||
| Current Valuation | 16.22 B | |||
| Shares Outstanding | 70.4 M | |||
| Price To Book | 10.55 X | |||
| Price To Sales | 5.90 X | |||
| Revenue | 2.71 B | |||
| Gross Profit | 1.94 B | |||
| EBITDA | 586.9 M | |||
| Net Income | 247.1 M | |||
| Cash And Equivalents | 708.6 M | |||
| Cash Per Share | 10.21 X | |||
| Total Debt | 1.05 B | |||
| Debt To Equity | 3.34 % | |||
| Current Ratio | 4.69 X | |||
| Book Value Per Share | 21.53 X | |||
| Cash Flow From Operations | 569.3 M | |||
| Earnings Per Share | 3.47 X | |||
| Market Capitalization | 15.99 B | |||
| Total Asset | 3.19 B | |||
| Retained Earnings | 287.4 M | |||
| Working Capital | 1.23 B | |||
| Current Asset | 190.76 M | |||
| Current Liabilities | 65.16 M | |||
Performance Metrics & Calculation Methodology
Insulet performance is measured on a risk-adjusted basis against benchmarks. Relative performance helps interpret behavior versus benchmarks or category peers. Insulet shows ROE of 18.12%, ROA of 9.43%.
For Insulet, this section uses periodic company reporting and market reference feeds and standardizes the results for cross-period comparison. Intraday timing differences may exist. Return and risk statistics are calculated from historical price series.